SAVA - NASDAQ

Cassava Sciences, Inc.

SAVA·NASDAQ

$1.96

-6.5%

HealthcareBiotechnology

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$94.44M

EPS-1.8800

P/E Ratio-1.04

Earnings Date03/16/2026

118.36M

Assets

-25%

3Y-50.0%

5Y+26.0%

10Y+513.0%

43.95M

Total Liabilities

272%

3Y+502.0%

5Y+1993.0%

10Y+6509.0%

74.40M

Total Equity

-49%

3Y-67.0%

5Y-19.0%

10Y+299.0%

Cassava Sciences, Inc. Funding & Solvency Profile

SAVA · NASDAQ

Current Assets

Cash & Cash Equivalents95.50M

Net Receivables0.00

Inventory0.00

Other Current Assets2.21M

Total Current Assets98 M

Non-Current Assets

Property, Plant & Equipment20.65M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets21 M

Total Assets

118.36M

Financial Health Analysis

Current Ratio

2.23x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.59x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

54 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

83% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Cassava Sciences, Inc. Balance Sheet

SAVA • NASDAQ

Cassava Sciences, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	95.5M	128.6M	121.1M	201M	233.4M	93.5M	23.1M	19.8M	10.5M	18.7M	31.3M	40.6M	49.8M	56.3M	73.1M	4.8M	35.8M	153.2M	86.6M	16.4M
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1M	0.0	0.0	1.3M	6.9M	25M	86.4M	140M	36.9M	118.5M	188M
Cash & Short-Term Investments	95.5M	128.6M	121.1M	201M	233.4M	93.5M	23.1M	19.8M	10.5M	18.7M	31.3M	40.6M	49.8M	56.3M	98.1M	91.2M	175.8M	190.1M	205.1M	204.4M
Net Receivables	0.0	947K	962K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1M	0.0	0.0	0.0	0.0
Accounts Receivables	0.0	947K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1M	0.0	0.0	0.0	0.0
Other Receivables	0.0	0.0	962K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	800K	759K	10.1M	662K	457K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Assets	2.2M	6.2M	6.8M	160K	10.4M	31K	268K	233K	184K	356K	392K	239K	265K	253K	358K	144K	2.7M	541K	303K	2.7M
Total Current Assets	97.7M	136.5M	129.6M	211.2M	244.5M	94M	23.3M	20M	10.7M	19.1M	31.7M	40.8M	50.1M	56.5M	98.5M	98.5M	178.5M	190.6M	205.4M	207.1M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	20.6M	21M	21.9M	23M	20.8M	306K	137K	100K	200K	300K	200K	100K	0.0	0.0	122K	285K	517K	774K	1.6M	1.3M
Intangible Assets	0.0	37K	176K	622K	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	0.0	37K	176K	622K	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	0.0	0.0	0.0	0.0	399K	0.0	0.0	-1K	-32K	-68K	27K	-23K	0.0	352K	352K	426K	3M	2M	644K	75K
Total Non-Current Assets	20.6M	21M	22M	23.6M	22.3M	306K	137K	99K	168K	232K	227K	77K	0.0	352K	474K	711K	3.5M	2.8M	2.3M	1.3M
Total Assets	118.4M	157.5M	151.7M	234.8M	266.8M	94.3M	23.5M	20.1M	10.8M	19.3M	31.9M	40.9M	50.1M	56.9M	99M	99.2M	182M	193.4M	207.6M	208.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	0.0	7.7M	10.6M	4M	7.1M	911K	453K	294K	424K	303K	1M	173K	445K	361K	464K	1.1M	1.3M	2.2M	3.6M	985K
Accounts Payable	0.0	7.7M	10.6M	4M	7.1M	911K	453K	294K	424K	303K	1M	173K	445K	361K	464K	1.1M	1.3M	2.2M	3.6M	985K
Accrued Expenses	0.0	4.1M	200K	2.3M	4.7M	719K	58K	61K	309K	335K	623K	652K	712K	853K	996K	2.1M	2.8M	3.6M	2.7M	6.7M
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	90K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	0.0	0.0	104K	97K	58K	90K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8M
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	835K	0.0	0.0	0.0	0.0	0.0	0.0	7.8M	10.9M	10.9M	14.3M	14.3M	14.3M	26.2M
Other Current Liabilities	43.8M	45K	3.4M	662K	631K	177K	696K	156K	399K	27K	894K	25K	644K	953K	915K	0.0	0.0	0.0	0.0	2.8M
Total Current Liabilities	43.8M	11.8M	14.2M	7.1M	12.5M	1.9M	1.4M	511K	1.1M	665K	2.6M	850K	1.8M	10M	13.3M	14.1M	18.5M	20.1M	20.7M	36.7M
NON-CURRENT LIABILITIES
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	33.3M	40.9M	51.8M	53.8M	68.2M	82.5M	93.9M
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	437K	435K	431K	1.4M	882K	0.0	0.0
Other Non-Current Liabilities	118K	79K	0.0	197K	194K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	553K	0.0
Total Non-Current Liabilities	118K	79K	0.0	232K	333K	235K	0.0	294K	424K	303K	1M	173K	445K	33.7M	41.3M	52.2M	55.2M	69M	83.1M	93.9M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-294K	-424K	-303K	-1M	-173K	-445K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations	0.0	0.0	0.0	139K	236K	293K	90K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	44M	11.8M	14.2M	7.3M	12.9M	2.1M	1.4M	511K	1.1M	665K	2.6M	850K	1.8M	43.7M	54.6M	66.3M	73.8M	89.2M	103.7M	130.5M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	475K	0.0	0.0	416K	0.0
Common Stock	48K	48K	42K	42K	40K	35K	190.7M	17K	7K	46K	46K	46K	45K	45K	45K	43K	42K	42K	44K	44K
Additional Paid-In Capital	0.0	550.8M	518.2M	511M	461.2M	267.1M	190.7M	183.6M	167.1M	164.1M	160M	156.5M	152.4M	148.7M	176.4M	162M	225.4M	218M	221.4M	214.7M
Retained Earnings	-496.1M	-405.1M	-380.8M	-283.6M	-207.3M	-174.9M	-168.6M	-164M	-157.4M	-145.5M	-130.6M	-116.5M	-104.1M	-135.7M	-132.2M	-129.6M	-117.6M	-114.1M	-118.1M	-136.5M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-900K	-800K	-700K	-700K	1K	1K	4K	128K	525K	347K	325K	584K	-372K
Other Total Stockholders' Equity	570.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-39K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	74.4M	145.7M	137.5M	227.5M	253.9M	92.2M	22.1M	19.6M	9.7M	18.6M	29.4M	40.1M	48.3M	13.1M	44.4M	32.9M	108.3M	104.3M	103.9M	77.9M
Total Equity	74.4M	145.7M	137.5M	227.5M	253.9M	92.2M	22.1M	19.6M	9.7M	18.6M	29.4M	40.1M	48.3M	13.1M	44.4M	32.9M	108.3M	104.3M	103.9M	77.9M
SUMMARY
Total Liabilities & Equity	118.4M	157.5M	151.7M	234.8M	266.8M	94.3M	23.5M	20.1M	10.8M	19.3M	31.9M	40.9M	50.1M	56.9M	99M	99.2M	182M	193.4M	207.6M	208.5M
Total Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1M	0.0	0.0	1.3M	6.9M	25M	86.4M	140M	36.9M	118.5M	188M
Total Debt	0.0	0.0	0.0	139K	236K	293K	90K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	-95.5M	-128.6M	-121.1M	-200.9M	-233.2M	-93.2M	-23M	-19.8M	-10.5M	-18.7M	-31.3M	-40.6M	-49.8M	-56.3M	-73.1M	-4.8M	-35.8M	-153.2M	-86.6M	-16.4M
Shares Outstanding	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896	48,307,896

SEC Filings

SAVA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	March 12, 2026	March 12, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 12, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 10, 2026	March 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 19, 2026	February 19, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 23, 2025	December 19, 2025	2025	View Filing
8-K/A 8-K/A 2025 (Amended) N/A	December 22, 2025	October 21, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 18, 2025	December 15, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 17, 2025	December 12, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 03, 2025	November 26, 2025	2025	View Filing
S-3 S-3 N/A	November 13, 2025	November 13, 2025		View Filing

Showing 1 to 10 of 393 filings

Related Guides

Blog Categories

Continue your SAVA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.